Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 16/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090658 | 0.92 | BDKRB1 (0.40) | ADRA2CBDKRB1ALDH1A1MAPT | |
| SCHEMBL4091292 | 0.92 | BDKRB1 (0.39) | ADRA2CBDKRB1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL4090579 | 0.92 | MAPT (0.41) | ADRA2CBDKRB1ALDH1A1MAPT | |
| SCHEMBL4091526 | 0.91 | ADRA2C (0.37) | ADRA2CBDKRB1ALDH1A1 | |
| SCHEMBL4095430 | 0.91 | BDKRB1 (0.38) | ADRA2CBDKRB1ALDH1A1 | |
| SCHEMBL4091242 | 0.89 | BDKRB1 (0.41) | BDKRB1 | |
| SCHEMBL4086000 | 0.88 | MAPT (0.44) | BDKRB1ALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL4081381 | 0.87 | BDKRB1 (0.41) | ADRA2CBDKRB1 | |
| SCHEMBL4093039 | 0.86 | BDKRB1 (0.51) | BDKRB1 | |
| SCHEMBL4085827 | 0.86 | BDKRB1 (0.41) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263598-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-11 | — | — | US | claimed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | claimed |
| US-8263598-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186899-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | ADRA2C 443/4885BDKRB1 1/4885ALDH1A1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.